Celldex Therapeutics Inc
NASDAQ:CLDX

  • LAST PRICE
    26.2100
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    --- / 26.2100
  • Day Range
    ---
  • 52 Week Range
    24.4300
    53.1800
  • Volume
    ---

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
CLDX
Celldex Therapeutics Inc
1.7B
-10.2x
---
SPRY
ARS Pharmaceuticals Inc
1.7B
-37.5x
---
SNDX
Syndax Pharmaceuticals Inc
1.9B
-6.0x
---
DAWN
Day One Biopharmaceuticals Inc
1.6B
-15.5x
---
BCYC
Bicycle Therapeutics PLC
1.7B
-7.4x
---
PRAX
Praxis Precision Medicines Inc
1.6B
-8.2x
---
As of 2024-11-12

Company Information

Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis and Eosinophilic Esophagitis. The Company’s bispecific antibody platform to support pipeline expansion with additional candidates for inflammatory diseases and oncology. Bispecific Platform includes CDX-585. CDX-585 combines its highly active PD-1 blockade and anti-ILT4 blockade to overcome immunosuppressive signals in T cells and myeloid cells, respectively.

Contact Information

Headquarters
53 Frontage Road, Suite 220HAMPTON, NJ, United States 08827
Phone
908-200-7500
Fax
302-655-5049

Executives

Independent Chairman of the Board
Karen Shoos
President, Chief Executive Officer, Director
Anthony Marucci
Chief Financial Office, Senior Vice President, Secretary
Sam Martin
Executive Vice President, Chief Scientific Officer
Tibor Keler
Senior Vice President, General Counsel
Freddy Jimenez

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$1.7B
Revenue (TTM)
$10.0M
Shares Outstanding
66.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.56
EPS
$-2.57
Book Value
$7.68
P/E Ratio
-10.2x
Price/Sales (TTM)
174.3
Price/Cash Flow (TTM)
---
Operating Margin
-1,871.27%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.